Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
Stock Information for Aptevo Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.